These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32001260)

  • 1. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
    Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
    Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
    Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
    Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
    Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
    Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
    Hayden A; Johnson PW; Packham G; Crabb SJ
    Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
    Zhu L; Yu CL; Zheng Y
    Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.
    Zou JX; Duan Z; Wang J; Sokolov A; Xu J; Chen CZ; Li JJ; Chen HW
    Mol Cancer Res; 2014 Apr; 12(4):539-49. PubMed ID: 24391143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
    Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
    Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
    Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation.
    Fujiwara T; Saitoh H; Inoue A; Kobayashi M; Okitsu Y; Katsuoka Y; Fukuhara N; Onishi Y; Ishizawa K; Ichinohasama R; Harigae H
    J Biol Chem; 2014 Mar; 289(12):8121-34. PubMed ID: 24492606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
    Lee JK; Kim KC
    Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
    Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
    Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
    Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
    Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
    Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
    PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
    Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
    Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
    García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
    Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
    Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
    Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
    Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
    Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
    Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
    J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.